REPAGLINIDE AND TROGLITAZONE IN TREATMENT OF TYPE II DIABETES MELLITUS

这是一项开放、随机、对照、平行的团体研究。第一阶段：经过四周的洗涤，受试者将被随机分配到研究治疗并进入14周的时期，在此期间剂量将升级到每种药物或其组合的固定、次最大剂量，之后将评估HbA1c并确定应答率。分析将在此阶段进行。第二阶段：为期8周，在此期间，对空腹血糖大于或等于120 mg/dl的受试者进行滴定，直到每种药物的最大剂量。第三阶段：在单一疗法中接受最大剂量曲格列酮治疗时未达到目标控制的受试者将接受测试剂量的瑞格列奈，然后接受联合治疗，包括滴定期和稳定期，总计10周。

This is an open, randomized, controlled, parallel group study. First phase: Following a four-week washout, subjects will be randomized to study therapy and enter a 14 week period in which dose will be escalated to a fixed, submaximal dose of each drug or their combination, after which HbA1c will be evaluated and response rate determined. Analysis will be performed at this stage. Second phase: An 8 week period in which subjects who have an FBG greater than or equal to 120 mg/dl are titrated until maximal dose of each drug. Third phase: subjects who do not achieve target control when treated with troglitazone on maximal dose in monotherapy will receive a test dose of repaglinide and subsequently be treated with combination therapy, including a titration period and a stabilzation period to a total for 10 weeks.